Guidance from the American Academy of Pediatrics on generic drugs was last published in 1987. The regulatory process for development of a new generic product in place of the reference brand-name drug requires extensive Food Drug and Administration (FDA) standards for similarity to expect the same safety and effectiveness profiles. Since the last guidance, the growth in biologic agents and the development of biosimilars as alternatives to the originator have become more common across the United S